肾脏迎来糖尿病治疗新纪元

Three different classes of diabetes medication are revolutionizing the prognosis of patients with chronic kidney disease By Tara Haelle MORE THAN ONE in seven people in the U.S. have chronic kidney disease, which was the ninth-leading cause of death worldwide in 2023. But until recently, just one class of drugs—called renin-angiotensin system (RAS) inhibitors— had been shown to slow progression of the ill- ness, and even those medications were only mod- estly effective. “For the first time there’s a realistic prospect of actually stopping kidney disease progression,” says Maarten Taal, a nephrologist at the Univer- sity of Nottingham in England. And the combi- nations raise hope of a day when the disease could actually be reversed, he says. …